Navigation Links
Abbott vs. Thailand has implications for innovation and access

Many of you have been following the Abbott Laboratories story regarding its Kaletra AIDS drug and the conflict with the government of Thailand over patent protection and drug pricing. Some of you may regard this as a relatively isolated tiff between a single drug company and another developing country. Others consider this to be a ......

Full article >>> iland, remarking that Abbott has spent over $300 million last year alone in humanitarian relief worldwide. Activists as well as shareholders supportive of the Abbott decision spar (fortunately peaceably).

Without taking sides, this sounds to me like a lose-lose situation out of a Shakespearean "tragicomedy," layered by miscommunication and blinkered outlooks. Both sides have valid points,......

Full article >>> ieved a short-term victory on Aluvia pricing, but it lost out on significant other life-saving medicines for their population. That being said, AIDS is a monumental problem in Thailand. The prevalence in that population is estimated at over one percent, which consequently makes AIDS one of the leading causes of death in that country. To a large exten......

Full article >>> s are exporting medicines to developing countries. That reason is called comparative advantage. The U.S. has a comparative advantage relative to other nations in quite a few industries. Aircraft is one of them, military technology is another, financial services also ranks high on the list and, of course, pharmaceuticals and medical technology are significant sources of comparative advantage.
......

Full article >>> t opportunity at medical diplomacy and a failed chance at improving the perception of the U.S. among other nations.

The efforts of U.S. companies to export healthcare technology and medical expertise to other nations becomes not just a business matter but something that should be part of our foreign policy and all the support and encouragement that entails.

So how does this broad......

Full article >>> usly speaking about the Civil War and arguing not only for his vision of a united United States but perhaps more importantly pointing out the state of mind required to achieve that vision. In our time, the dogma that innovation justifies high prices is not necessarily invalid, but we need to think anew and act anew.

Previous articles by Ogan Gurel



Source:wistechnology.com By Ogan Gurel 05/01/07


Related biology technology :

1. A prognosis for GE and Abbott Diagnostics
2. Wisconsin court halts Abbotts sale of genotyping products
3. Wisconsin court affirms damages in Innogenetics, Abbott patent case
4. Abbott Labs campus in Kenosha could send ripples through local biotech
5. Abbott Executive Jim Tyree Takes IBIO Helm
6. Promega Announces Agreement with Abbott
7. Changes to U.S. patent law must nurture our culture of innovation
8. Visions: Benson touts embedded innovation
9. UW System must remove barriers to innovation
10. In western Wisconsin, the innovation economy is growing
11. Scott Converse, UW-Madison School of Business, on the innovation mind-set
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... MILPITAS, Calif. , Feb. 17, 2017 /PRNewswire/ ... posters detailing data on its oral peptide drug ... Congress of the European Crohn,s and Colitis ... in Barcelona, Spain from ... The posters detail preclinical data on Protagonist drug ...
(Date:2/16/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the ... for triple negative breast cancer (TNBC), announced today their completion ... program. The YEi Start in France ... grow their business in France and ... to complete an intensive one week immersion in ...
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
Breaking Biology News(10 mins):